136 related articles for article (PubMed ID: 31065112)
21. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
[TBL] [Abstract][Full Text] [Related]
22. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer.
Thomsen FB; Røder MA; Jakobsen H; Langkilde NC; Borre M; Jakobsen EB; Frey A; Lund L; Lunden D; Dahl C; Brasso K
Clin Genitourin Cancer; 2019 Aug; 17(4):e814-e821. PubMed ID: 31196798
[TBL] [Abstract][Full Text] [Related]
23. Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study.
Bergengren O; Garmo H; Bratt O; Holmberg L; Johansson E; Bill-Axelson A
Eur Urol Oncol; 2018 May; 1(1):37-45. PubMed ID: 31100227
[TBL] [Abstract][Full Text] [Related]
24. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer outcomes for men who present with symptoms at diagnosis.
Beckmann KR; O'Callaghan ME; Ruseckaite R; Kinnear N; Miller C; Evans S; Roder DM; Moretti K;
BJU Int; 2017 Jun; 119(6):862-871. PubMed ID: 27489140
[TBL] [Abstract][Full Text] [Related]
26. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
[TBL] [Abstract][Full Text] [Related]
27. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
[TBL] [Abstract][Full Text] [Related]
28. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
29. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.
Ørsted DD; Bojesen SE; Nielsen SF; Nordestgaard BG
Eur Urol; 2011 Oct; 60(4):691-8. PubMed ID: 21705134
[TBL] [Abstract][Full Text] [Related]
30. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
31. Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay.
Lynch JA; Rothney MP; Salup RR; Ercole CE; Mathur SC; Duchene DA; Basler JW; Hernandez J; Liss MA; Porter MP; Wright JL; Risk MC; Garzotto M; Efimova O; Barrett L; Berse B; Kemeter MJ; Febbo PG; Dash A
Am J Manag Care; 2018 Jan; 24(1 Suppl):S4-S10. PubMed ID: 29337486
[TBL] [Abstract][Full Text] [Related]
32. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study.
Wallis CJ; Lo K; Lee Y; Krakowsky Y; Garbens A; Satkunasivam R; Herschorn S; Kodama RT; Cheung P; Narod SA; Nam RK
Lancet Diabetes Endocrinol; 2016 Jun; 4(6):498-506. PubMed ID: 27165609
[TBL] [Abstract][Full Text] [Related]
33. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.
Schmid M; Sammon JD; Reznor G; Kapoor V; Speed JM; Abdollah FA; Sood A; Chun FK; Kibel AS; Menon M; Fisch M; Sun M; Trinh QD
BJU Int; 2016 Aug; 118(2):221-9. PubMed ID: 26074405
[TBL] [Abstract][Full Text] [Related]
34. Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners.
Hartung TJ; Moustsen IR; Larsen SB; Wreford Andersen EA; Suppli NP; Johansen C; Tjønneland A; Friberg AS; Kjær SK; Brasso K; Kessing LV; Mehnert A; Dalton SO
J Cancer Surviv; 2021 Aug; 15(4):536-545. PubMed ID: 33051756
[TBL] [Abstract][Full Text] [Related]
35. Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
Beckmann K; Kinsella N; Olsson H; Wallerstedt Lantz A; Nordstrom T; Aly M; Adolfsson J; Eklund M; Van Hemelrijck M
BMC Urol; 2019 Aug; 19(1):73. PubMed ID: 31383015
[TBL] [Abstract][Full Text] [Related]
36. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
37. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
Berglund A; Garmo H; Robinson D; Tishelman C; Holmberg L; Bratt O; Adolfsson J; Stattin P; Lambe M
Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
[TBL] [Abstract][Full Text] [Related]
38. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study.
Adelborg K; Szépligeti SK; Holland-Bill L; Ehrenstein V; Horváth-Puhó E; Henderson VW; Sørensen HT
BMJ; 2018 Jan; 360():k96. PubMed ID: 29386181
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.
Hoffman KE; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin MJ; Ross R; D'Amico AV
Cancer; 2010 Jun; 116(11):2590-5. PubMed ID: 20310055
[TBL] [Abstract][Full Text] [Related]
40. Prostate cancer in 432 men aged <50 years in the prostate-specific antigen era: a new outlook.
Gielchinsky I; Chang J; Cusick T; Delprado W; Nguyen Q; Yuen C; Savdie R; Böhm M; Haynes AM; Scheltema MJ; Stricker PD
BJU Int; 2018 Nov; 122 Suppl 5():35-41. PubMed ID: 30303599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]